

# Tove Olafsen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11105064/publications.pdf>

Version: 2024-02-01

56  
papers

2,646  
citations

172457

29  
h-index

182427

51  
g-index

57  
all docs

57  
docs citations

57  
times ranked

2863  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibody Vectors for Imaging. <i>Seminars in Nuclear Medicine</i> , 2010, 40, 167-181.	4.6	182
2	Optimizing Radiolabeled Engineered Anti-p185HER2 Antibody Fragments for In vivo Imaging. <i>Cancer Research</i> , 2005, 65, 5907-5916.	0.9	158
3	Engineered antibody fragments for immuno-PET imaging of endogenous CD8 <sup>+</sup> T cells in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 1108-1113.	7.1	148
4	Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. <i>Cancer Research</i> , 2005, 65, 622-31.	0.9	144
5	Antibodies for Molecular Imaging of Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2008, 14, 191-197.	2.0	132
6	Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells. <i>Journal of Immunological Methods</i> , 1997, 204, 77-87.	1.4	121
7	Immuno-PET of Murine T Cell Reconstitution Postadoptive Stem Cell Transplantation Using Anti-CD4 and Anti-CD8 Cys-Diabodies. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1258-1264.	5.0	104
8	Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. <i>Protein Engineering, Design and Selection</i> , 2004, 17, 21-27.	2.1	102
9	PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. <i>Journal of Nuclear Medicine</i> , 2007, 48, 304-10.	5.0	92
10	Radioiodinated versus Radiometal-Labeled Anti-CEA Carcinoembryonic Antigen Single-Chain Fv-Fc Antibody Fragments: Optimal Pharmacokinetics for Therapy. <i>Cancer Research</i> , 2007, 67, 718-726.	0.9	86
11	Characterization of engineered anti-p185HER-2 (scFv-CH3) <sub>2</sub> antibody fragments (minibodies) for tumor targeting. <i>Protein Engineering, Design and Selection</i> , 2004, 17, 315-323.	2.1	75
12	Fusion of Gaussia Luciferase to an Engineered Anti-carcinoembryonic Antigen (CEA) Antibody for In Vivo Optical Imaging. <i>Molecular Imaging and Biology</i> , 2007, 9, 267-277.	2.6	73
13	Targeting, Imaging, and Therapy Using a Humanized Antiprostate Stem Cell Antigen (PSCA) Antibody. <i>Journal of Immunotherapy</i> , 2007, 30, 396-405.	2.4	68
14	Recombinant Anti-CD20 Antibody Fragments for Small-Animal PET Imaging of B-Cell Lymphomas. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1500-1508.	5.0	68
15	Reduction of Kidney Uptake in Radiometal Labeled Peptide Linkers Conjugated to Recombinant Antibody Fragments. Site-Specific Conjugation of DOTA-Peptides to a Cys-Diabody. <i>Bioconjugate Chemistry</i> , 2002, 13, 985-995.	3.6	63
16	Humanized Radioiodinated Minibody For Imaging of Prostate Stem Cell Antigen-Expressing Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 7488-7496.	7.0	63
17	Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins. <i>Protein Engineering, Design and Selection</i> , 2010, 23, 789-798.	2.1	60
18	Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. <i>Nature Protocols</i> , 2006, 1, 2048-2060.	12.0	57

#	ARTICLE	IF	CITATIONS
19	Bifunctional antibody-Renilla luciferase fusion protein for in vivo optical detection of tumors. <i>Protein Engineering, Design and Selection</i> , 2006, 19, 453-460.	2.1	56
20	An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1529-1538.	6.4	55
21	ImmunoPET using engineered antibody fragments: fluorine-18 labeled diabodies for same-day imaging. <i>Tumor Biology</i> , 2012, 33, 669-677.	1.8	55
22	Cys-diabody Quantum Dot Conjugates (ImmunoQdots) for Cancer Marker Detection. <i>Bioconjugate Chemistry</i> , 2009, 20, 1474-1481.	3.6	52
23	Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange. <i>Protein Engineering, Design and Selection</i> , 2001, 14, 1025-1033.	2.1	47
24	Site-Specific, Thiol-Mediated Conjugation of Fluorescent Probes to Cysteine-Modified Diabodies Targeting CD20 or HER2. <i>Bioconjugate Chemistry</i> , 2008, 19, 2527-2534.	3.6	41
25	Anti-CA19-9 Diabody as a PET Imaging Probe for Pancreas Cancer. <i>Journal of Surgical Research</i> , 2011, 170, 169-178.	1.6	41
26	ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies). <i>Protein Engineering, Design and Selection</i> , 2010, 23, 243-249.	2.1	39
27	Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors. <i>Protein Engineering, Design and Selection</i> , 2008, 22, 209-216.	2.1	38
28	Unexpected Expression Pattern for Glycosylphosphatidylinositol-anchored HDL-binding Protein 1 (GPIHBP1) in Mouse Tissues Revealed by Positron Emission Tomography Scanning. <i>Journal of Biological Chemistry</i> , 2010, 285, 39239-39248.	3.4	36
29	Targeting CEA in Pancreas Cancer Xenografts with a Mutated scFv-Fc Antibody Fragment. <i>EJNMMI Research</i> , 2011, 1, 24.	2.5	31
30	Anti-carcinoembryonic Antigen Single-chain Variable Fragment Antibody Variants Bind Mouse and Human Neonatal Fc Receptor with Different Affinities That Reveal Distinct Cross-species Differences in Serum Half-life. <i>Journal of Biological Chemistry</i> , 2012, 287, 22927-22937.	3.4	30
31	The PET-Tracer 89Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment. <i>Cancer Research</i> , 2020, 80, 2903-2913.	0.9	30
32	Recombinant carcinoembryonic antigen as a reporter gene for molecular imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 104-114.	6.4	22
33	Fc Engineering: Serum Half-Life Modulation Through FcRn Binding. <i>Methods in Molecular Biology</i> , 2012, 907, 537-556.	0.9	22
34	In Vivo Eradication of a Rituximab-Resistant Human CD20+ B Cell Lymphoma by Rituximab-CpG Oligodeoxynucleotide Conjugate Is Mediated by Natural Killer Cells and Complement.. <i>Blood</i> , 2009, 114, 723-723.	1.4	22
35	Cloning and sequencing of V genes from anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: Location of lysine residues and implications for radiolabeling. <i>Nuclear Medicine and Biology</i> , 1995, 22, 765-771.	0.6	21
36	IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eukaryotic cells. <i>Immunotechnology: an International Journal of Immunological Engineering</i> , 1998, 4, 141-153.	2.4	19

#	ARTICLE	IF	CITATIONS
37	Multimodal imaging guides surgical management in a preclinical spinal implant infection model. JCI Insight, 2019, 4, .	5.0	19
38	Evaluation of an anti-p185HER2 (scFv-CH2-CH3) <sub>2</sub> fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-d-GEEEK. Nuclear Medicine and Biology, 2009, 36, 671-680.	0.6	18
39	Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-Based PET Radiotracers. Journal of Nuclear Medicine, 2017, 58, 175-180.	5.0	17
40	Abundant Tyrosine Residues in the Antigen Binding Site in Anti-Osteosarcoma Monoclonal Antibodies Tp-1 and Tp-3: Application to radiolabeling. Acta Oncol <sup>3</sup> gica, 1996, 35, 297-301.	1.8	16
41	Recombinant chimeric OKT3 scFv IgM antibodies mediate immune suppression while reducing T cell activation in vitro. European Journal of Immunology, 2001, 31, 94-106.	2.9	16
42	Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors. EJNMMI Research, 2020, 10, 10.	2.5	16
43	Cytotoxicity of Antiosteosarcoma Recombinant Immunotoxins Composed of TP-3 Fv Fragments and a Truncated Pseudomonas Exotoxin A. Journal of Immunotherapy, 2001, 24, 144-150.	2.4	14
44	Positron Emission Tomography Imaging of Endometrial Cancer Using Engineered Anti-EMP2 Antibody Fragments. Molecular Imaging and Biology, 2013, 15, 68-78.	2.6	14
45	Protein Targeting Constructs in Alpha Therapy. Current Radiopharmaceuticals, 2011, 4, 197-213.	0.8	13
46	Levels of Murine, but Not Human, CXCL13 Are Greatly Elevated in NOD-SCID Mice Bearing the AIDS-Associated Burkitt Lymphoma Cell Line, 2F7. PLoS ONE, 2013, 8, e72414.	2.5	11
47	Evaluation of Two Internalizing Carcinoembryonic Antigen Reporter Genes for Molecular Imaging. Molecular Imaging and Biology, 2011, 13, 526-535.	2.6	10
48	Complement-mediated lysis of cultured osteosarcoma cell lines using chimeric mouse/human TP-1 IgG1 and IgG3 antibodies. Cancer Immunology, Immunotherapy, 1999, 48, 411-418.	4.2	6
49	Characterization of a double-sided silicon strip detector autoradiography system. Medical Physics, 2015, 42, 575-584.	3.0	6
50	Numerical Comparison of Iodine-Based and Indium-Based Antibody Biodistributions. Cancer Biotherapy and Radiopharmaceuticals, 2014, 29, 91-98.	1.0	4
51	Safety and Biodistribution Profile of Poly(styrenyl acetal trehalose) and Its Granulocyte Colony Stimulating Factor Conjugate. Biomacromolecules, 2022, 23, 3383-3395.	5.4	4
52	Serial digital autoradiography with a silicon strip detector as a high resolution imaging modality for TRT dosimetry. , 2007, , .		2
53	Positron Emission Tomographic Imaging of Iodine 124 Anti-“Prostate Stem Cell Antigen” Engineered Antibody Fragments in LAPC-9 Tumor-“Bearing Severe Combined Immunodeficiency Mice. Molecular Imaging, 2013, 12, 7290.2012.00033.	1.4	2
54	Engineering of the Fc Region for Improved PK (FcRn Interaction). , 2010, , 411-430.		2

#	ARTICLE	IF	CITATIONS
55	Generation of Single-Chain Fv Fragments and Multivalent Derivatives scFv-Fc and scFv-CH3 (Minibodies). , 2010, , 69-84.		2
56	Imaging Tumor Xenografts Using Radiolabeled Antibodies. , 2010, , 491-506.		0